What the FDA labels say about taking them together
Everolimus and tacrolimus
Everolimus's FDA label (Zortress) of February 12, 2026 names tacrolimus in its drug interactions section; the tacrolimus labels PlainMeds reads (4) do not name everolimus. The everolimus label: “Reduced doses of tacrolimus should be used in combination with Zortress in order to minimize the potential risk of nephrotoxicity [ s ee Indications and Usage, Clinical Pharmacology (12.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the tacrolimus FDA label on DailyMed (effective July 17, 2026, Stellon Biotech Inc.).
What does the everolimus label say about tacrolimus?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsThere is little to no pharmacokinetic interaction of tacrolimus on everolimus, and consequently, dose adjustment of Zortress is not necessary when Zortress is coadministered with tacrolimus.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsReduced doses of tacrolimus should be used in combination with Zortress in order to minimize the potential risk of nephrotoxicity [ s ee Indications and Usage (1.2), Clinical Pharmacology (12.
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the tacrolimus label say about everolimus?
Tacrolimus's label (effective July 17, 2026) and its 3 other brand-application labels do not name everolimus in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tacrolimus), Stellon Biotech Inc., effective July 17, 2026 (SPL set 6b89e8a4-9f11-42e3-8e79-fe617e7c461f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Tacrolimus | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | Organ transplant rejection, Eczema (atopic dermatitis) |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $0.970 per gram 0.1% ointment |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once